Carocell Bio Announced as Winner in Inaugural ‘Boston Bootcamp’ Competition

boston bootcamp winner, Carocell Bio

London – 27 March 2024 – Today, Carocell Bio, the biotechnology company revolutionising the treatment of eczema with novel peptide technology, announced that it was one of four winners in the recent Boston Bootcamp competition for companies looking to expand into the Massachusetts (MA) Life Sciences cluster. The competition attracted a large number of entries from eligible UK-based companies. Carocell Bio and its platform, business proposition, and team clearly stood out to the expert trans-Atlantic judging panel amongst the very high-quality and diverse applicant pool.

The programme includes three days of preparatory sessions, workshops, 1-1 meetings and numerous networking opportunities in Boston with various key players across the ecosystem, including potential investors, R&D partners, recruiters, academics, local hubs, as well as operational and IP specialists. The winners also received official recognition at the One Nucleus Annual Awards dinner on 21st March.

Carocell Bio’s candidate peptide-based treatment JEL3108 provides an innovative approach treating eczema (atopic dermatitis) through an anti-inflammatory, allosterically binding MAP kinase-inhibiting mechanism. Eczema is the most common skin disease, with current treatment options often carrying significant safety risks. JEL3108 has been shown to work in biopsies from patients with eczema and could revolutionise the safe management of eczema. With continued use, it has the potential to stop eczema coming back. As skin ageing is also linked to inflammation, the Company’s patented peptide formulations could also potentially be used as an anti-ageing skin treatment.

The Boston Bootcamp programme, organised and hosted by the Cambridge, UK-based not-for-profit Life Sciences & Healthcare membership organisation, One Nucleus, has been developed as an effective bridge between the One Nucleus members and one of the world’s top locations for the Life Sciences – Boston. The programme follows the outputs of a session held at the BIO International Convention in 2023 that identified numerous knowledge gaps for emerging UK companies, including how to navigate the MA cluster and opportunities to provide beneficial and targeted interventions. The overall goal is to capitalise on existing business-to-business activity to further increase two-way deal flow.

More articles